Re-Anticoagulation after Warfarin-Related Intracerebral Hemorrhage in Patients with Mechanical Heart Valves: The Clinical Dilemma

Seminars in Cerebrovascular Diseases and Stroke

Volumn 5, Issue 3, 2005, Pages 221-224

  Park, Soojin ^a   Kase, Carlos S ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

factor VII; intracerebral hemorrhage; re anticoagulation; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; FLUCONAZOLE; FRESH FROZEN PLASMA; PHYTOMENADIONE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; VITAMIN K GROUP; WARFARIN;

ADULT; APHASIA; ARTICLE; BRAIN HEMORRHAGE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEADACHE; HEART VALVE PROSTHESIS; HOMONYMOUS HEMIANOPIA; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MYCOSIS; NAUSEA; PRIORITY JOURNAL; THROMBOEMBOLISM;

EID: 33745484284     PISSN: 15289931     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.scds.2006.03.002     Document Type: Article

References (38)

1. Sjöblom L., Hardemark H.G., Lindgren A., et al. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy. a Swedish multicenter study. Stroke 32 (2001) 2567-2574
2. Rosand J., Eckman M.H., Knudsen K.A., et al. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 164 (2004) 880-884
3. Salem D.N., Stein P.D., Al-Ahmad A., et al. Antithrombotic therapy in valvular heart disease-native and prosthetic. the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 457S-482S
4. Devereaux P.J., Anderson D.R., Gardner M.J., et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation. observational study. BMJ 323 (2001) 1218-1222
5. Ariesen M.J., Claus S.P., Rinkel G.J.E., et al. Risk factors for intracerebral hemorrhage in the general population. a systematic review. Stroke 34 (2003) 2060-2066
6. Gorter J.W., and Stroke Prevention in Reversible Ischemia Trial (SPIRIT) and European Atrial Fibrillation Trial (EAFT) Study Groups. Major bleeding during anticoagulation after cerebral ischemia. patterns and risk factors. Neurology 53 (1999) 1319-1327
7. Ariesen M.J., Algra A., Warlow C.P., et al. Predictors of risk of intracerebral haemorrhage in patients with a history of TIA or minor ischaemic stroke. J Neurol Neurosurg Psychiatry 77 (2006) 92-94
8. Hart R.G., Tonarelli S.B., and Pearce L.A. Avoiding central nervous system bleeding during antithrombotic therapy. recent data and ideas. Stroke 36 (2005) 1588-1593
9. Wintzen A.R., de Jonge H., Loeliger E.A., et al. The risk of intracerebral hemorrhage during oral anticoagulant treatment. a population study. Ann Neurol 16 (1984) 553-558
10. Babikian V.L., Kase C.S., Pessin M.S., et al. Intracerebral hemorrhage in stroke patients anticoagulated with heparin. Stroke 20 (1989) 1500-1503 (letter)
11. Smith E.E., Rosand J., Knudsen K.A., et al. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology 59 (2002) 193-197
12. Rosand J., Hylek E.M., O'Donnell H.C., et al. Warfarin-associated hemorrhage and cerebral amyloid angiopathy. a genetic and pathologic study. Neurology 55 (2000) 947-951
13. Hart R.G., Boop B.S., and Anderson D.C. Oral anticoagulants and intracranial hemorrhage. facts and hypotheses. Stroke 26 (1995) 1471-1477
14. Heck A.M., DeWitt B.A., and Lukes A.L. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm 57 (2000) 1221-1227
15. Hale W.E., Perkins L.L., May F.E., et al. Vitamin E effect on symptoms and laboratory values in the elderly. J Am Diet Assoc 86 (1986) 625-629
16. Huijgens P.C., van den Berg C.A., Imandt L.M., et al. Vitamin E and platelet aggregation. Acta Haematol 65 (1981) 217-218
17. Steiner M. Vitamin E, a modifier of platelet function. rationale and use in cardiovascular and cerebrovascular disease. Nutr Rev 57 (1999) 306-309
18. Machlin L.J. Clinical uses of vitamin E. Acta Vitaminol Enzymol 7 suppl (1985) 33-43
19. Garewal H.S., and Diplock A.T. How 'safe' are antioxidant vitamins?. Drug Saf 13 (1995) 8-14
20. Goldstein J.N., Thomas S.H., Frontiero V., et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke 37 (2006) 151-155
21. Schulman S. Care of patients receiving long-term anticoagulant therapy. N Engl J Med 349 (2003) 675-683
22. Steiner T., Rosand J., and Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy. current practices and unresolved questions. Stroke 37 (2006) 256-262
23. Makris M., Greaves M., Phillips W.S., et al. Emergency oral anticoagulant reversal. the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 77 (1997) 477-480
24. Roddie P.H., Stirling C., Mayne E.E., et al. Thrombosis and disseminated intravascular coagulation following treatment with the prothrombin complex concentrate, DEFIX. Thromb Haemost 81 (1999) 667 (letter)
25. Freeman W.D., Brott T.G., Barrett K.M., et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 79 (2004) 1495-1500
26. Brody D.L., Aiyagari V., Shackleford A.M., et al. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2 (2005) 263-267
27. Kase C.S. Hemostatic treatment in the early stage of intracerebral hemorrhage. the recombinant factor VIIa experience. Stroke 36 (2005) 2321-2322
28. Wijdicks E.F., Schievink W.I., Brown R.D., et al. The dilemma of discontinuation of anticoagulation therapy for patients with intracranial hemorrhage and mechanical heart valves. Neurosurgery 42 (1998) 769-773
29. Phan T.G., Koh M., and Wijdicks E.F. Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk. Arch Neurol 57 (2000) 1710-1713
30. De Vleeschouwer S., Van Calenbergh F., van Loon J., et al. Risk analysis of thrombo-embolic and recurrent bleeding events in the management of intracranial haemorrhage due to oral anticoagulation. Acta Chir Belg 105 (2005) 268-274
31. Butler A., and Tait R.C. Restarting oral anticoagulation in prosthetic heart valve patients after intracranial haemorrhage. a 2-year follow-up. Br J Haematol 103 (1998) 1064-1066
32. Bertram M., Bonsanto M., Hacke W., et al. Managing the therapeutic dilemma. patients with spontaneous intracerebral hemorrhage and urgent need for anticoagulation. J Neurol 247 (2000) 209-214
33. Yasaka M., Minematsu K., Naritomi H., et al. Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost 89 (2003) 278-283
34. Butchart E.G., Payne N., Hui-Hua L., et al. Better anticoagulation control improves survival after valve replacement. J Thor Cardiovasc Surg 123 (2002) 715-723
35. Estol C.J., and Kase C.S. Need for continued use of anticoagulants after intracerebral hemorrhage. Curr Treat Options Cardiovasc Med 5 (2003) 201-209
36. Eckman M.H., Rosand J., Knudsen K.A., et al. Can patients be anticoagulated after intracerebral hemorrhage?. a decision analysis. Stroke 34 (2003) 1710-1716
37. Rosengart T.K. Anticoagulation self-testing after heart valve replacement. J Heart Valve Dis 11 (2002) S61-S65
38. Horstkotte D., and Piper C. Improvement of oral anticoagulation therapy by INR self-management. J Heart Valve Dis 13 (2004) 335-338